Nueva oportunidad de fondos prioritarios del NIH para investigaciones relacionadas al Zika

Imagen de Giovanna Guerrero-Medina


Fecha Límite: 

Viernes, 1 marzo 2019

Favor ver abajo para una oportunidad de fondos urgentes para investigaciones sobre complicaciones relacionadas al Zika. Propuestas sometidas para estea oportunidad tendrán prioridad y urgencia en la revisión por pares y en la entrega de fondos

Funding Opportunity Title: Rapid Assessment of Zika Virus (ZIKV) Complications (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to provide an expedited (rapid) funding mechanism for research on Zika virus (ZIKV) and its complications.  ZIKV is a single-stranded RNA virus of the Flaviviridae family. It is transmitted to humans primarily through the bites of infected Aedes mosquitos, though both perinatal/in utero and sexual transmission have been reported.  Initially discovered in 1947, it has been reported in the Americas since 2014, with a major outbreak in Brazil starting in 2015.  Disease is seen in about 20% of infected people and is usually self-limited.  However, a possible association between ZIKV infection in pregnant women and severe microcephaly in their babies has been very concerning and prompted the World Health Organization to declare this potential complication a public health emergency. Additionally the virus has been found in blood, fueling growing concerns about the risk of transfusion-transmission with particular concern over severe outcomes in at risk transfusion recipient populations such as women who are pregnant. 

Application Due Date(s)

Applications will be accepted on a rolling basis, beginning on April 20, 2016.

Earliest Start Date

Rapid applications will be handled on an expedited review and award basis to meet the goals of this program.

Award Budget

Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year.

Areas of high priority include, but are not limited to, the following:

  • Demonstrate the causative role of infection in pregnancy with ZIKV in the etiology of fetal microcephaly, structural brain defects, and other congenital malformations
  • Basic research to understand the ZIKV infection pathogenesis and transmission to the fetus, whether in-utero, postpartum, or breastfeeding
  • Population-based studies to characterize the epidemiology of ZIKV infection in the mother-infant dyad
  • Clinical studies to improve the understanding of the mechanisms and risks of maternal-to-child transmission of ZIKV
  • Determine the timeline for when and how women transmit ZIKV to the fetus
  • Strategies to prevent transmission of ZIKV to the fetus after infection in the mother
  • Studies to determine the optimal screening for and management of ZIKV infection in pregnant women and in exposed fetuses
  • Studies to understand the mechanisms by which ZIKV affects the developing nervous system and other organ systems
  • Studies to characterize the association of ZIKA virus infection with ocular phenotypes
  • Research to develop lab-based or point-of-care diagnosis for ZIKV using saliva as a biofluid
  • Studies to characterize the outcome of viral infection on craniofacial skeletal and dental phenotype with or without microcephaly
  • Studies to understand pregnancy outcomes in women infected with ZIKV
  • Studies to identify sequelae in infants infected with ZIKV as well as potential sequelae in exposed but uninfected infants
  • Strategies to identify neurologic and other manifestations in infants with and without microcephaly such as developmental delays and other neurologic or physical disorders
  • Studies to assess and characterize the natural history and long-term neurodevelopmental consequences of ZIKV infection in children
  • Strategies to identify effective treatments for exposed infants with and without microcephaly as they develop into childhood.  Such strategies must take into account cultural acceptance and resources.
  • Investigations of mediating and moderating factors affecting variability in neurodevelopmental, behavioral, and socio-emotional impact of ZIKV exposure on infants prenatally and postnatally
  • Develop novel, simple, feasible and cost-effective testing methods and/or strategies for infection screening during pregnancy
  • Develop novel, simple, rapid, feasible and cost effective testing methods and/or strategies for infection screening in the infant
  • Develop culturally sensitive strategies to increase knowledge about the relative efficacy of contraceptive methods, and use that knowledge to plan for pregnancy
  • Strategies to integrate the discussion of risk of ZIKV infection into contraceptive counseling and pre-pregnancy and prenatal care at medical facilities in ZIKV endemic areas
  • Determine long-term implications of ZIKV infection in non-pregnant women and men including impact on fertility and subsequent pregnancy
  • Studies to ascertain if ZIKV is present in reproductive fluids such as semen, cervical mucus, vaginal secretions and/or follicular fluid; persistence of ZIKV in these fluids; and the mechanisms by which ZIKV enters the reproductive tract
  • Studies on effects of ZIKV on in vitro fertilization
  • Studies on whether ZIKV can be transmitted by direct sexual contact or artificial reproductive technology procedures
  • Once causality is demonstrated, studies on vaccine development in pregnant women and children
  • Once causality is demonstrated, development of methods to explain risk of ZIKV infection and  
  • risk of harm to the fetus to pregnant women and women who are planning to become pregnant.
  • Basic research to understand ZIKV infection, replication, pathogenesis, transmission, immune
  • responses and immunological interactions with other flaviviruses
  • Studies on the evolution and emergence of ZIKV including the identification of factors that affect
  • host-range and virulence
  • Natural history studies of ZIKV in mosquitos, non-human primates and humans, with particular
  • emphasis on hosts(s) reservoirs and cross-species transmission
  • Basic research on the biology of the mosquito vectors, vector competence studies for replication
  • and transmission of ZIKV, host-virus interaction and studies on novel vector control methods
  • Development of novel diagnostic, vaccine and therapeutic strategies against Zika
  • Characterization of the prevalence of the virus among blood donors in different geographical regions
  • Quantitation and dynamics of the evolution of viremia in blood donors
  • Transmissibility studies in relevant animal models
  • Dynamics of viremia in transfusion recipients post transfusion
  • Development of Zika screening and confirmatory assays
  • Transfusion-transmission studies
  • Impact of Zika infection in patients who are chronically transfused such as patients with Sickle Cell disease or other monogenic chronic disease
  • Evaluations of potential strategies to reduce or prevent Zika transmission by blood transfusion



Categorías de Contenido: